XPOVIO® is the first and only exportin 1 (XPO1) inhibitor approved in Taiwan. Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to...
The partnership will help train XtalPi's models to accurately predict efficacy and safety parameters, increasing the success rate of drug design. Excelra, a leading global Data Analytics...
A novel third-generation antipsychotic drug lead with the potential to simultaneously treat negative and cognitive symptoms of schizophrenia. Schizophrenia is a serious mental disorder that affects...
Researchers from the Hong Kong University of Science and Technology (HKUST) discover molecular mechanism that could provide key guidance in development of drugs for cancer. Planar Cell Polarity (PCP)...
